Antiviral Drugs - Fiji | Statista Market Forecast

The projected revenue in the Antiviral Drugs market for Fiji is expected to reach US$711.60k in 2024.
It is estimated that the revenue will show an annual growth rate (CAGR 2024-2029) of 1.75%, resulting in a market volume of US$776.00k by 2029.
When compared globally, United States is anticipated to generate the highest revenue, with US$30.64bn in 2024.
Fiji's antiviral drug market is expanding rapidly due to increasing demand for effective treatments against viral infections.

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

HIV
Hepatitis B and hepatitis C
Ebola
COVID-19

Vaccines
Antibiotics
Immunosuppressants
In vitro diagnostics and rapid tests

Antiviral drugs have been gaining popularity in the global market due to the COVID-19 pandemic. Fiji, being a small island country in the South Pacific, has also been impacted by the pandemic. The Antiviral Drugs market in Fiji has been developing in response to the increasing demand for antiviral medication.

Customer preferences: Customers in Fiji have been showing a preference for antiviral drugs due to the rising number of COVID-19 cases. The pandemic has made people more conscious of their health and has led to an increase in demand for antiviral medication. Additionally, there has been a rise in cases of other viral diseases such as dengue fever and influenza, which has further increased the demand for antiviral drugs.

Trends in the market: The Antiviral Drugs market in Fiji has been growing due to the increasing demand for antiviral medication. The market has seen a rise in the production and import of antiviral drugs to meet the growing demand. The trend is expected to continue in the coming years as the pandemic continues to impact the country and the world.

Local special circumstances: Fiji is a small island nation that heavily relies on tourism for its economy. However, the pandemic has severely impacted the tourism industry, leading to a decline in the country's economy. The government has been taking measures to control the spread of the virus, such as imposing lockdowns and curfews, which has led to a rise in demand for antiviral drugs. Additionally, the country's healthcare infrastructure is not well-equipped to handle a large number of COVID-19 cases, which has further increased the demand for antiviral medication.

Underlying macroeconomic factors: The Antiviral Drugs market in Fiji is primarily driven by the impact of the COVID-19 pandemic on the country. The pandemic has led to a rise in demand for antiviral medication, which has resulted in the growth of the market. Additionally, the decline in the tourism industry has led to a shift in the country's economy, with a greater focus on healthcare and pharmaceuticals. The government has been taking measures to support the healthcare industry, which has also contributed to the growth of the Antiviral Drugs market in Fiji.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.